Three of the company’s prototype genome-sequencing assays were evaluated using samples from lung cancer patients. Early support for the concept was demonstrated with detection rates ranging from 38% to 51% in participants in participants with early-stage lung cancer at 98% specificity.
A University of Hawai'i Cancer Center researcher has identified how some cancer cells are made to move during metastasis. The research provides a better understanding of how cancer spreads and may create new opportunities for cancer drug development.
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.